Stress Echocardiography to Detect Exercise Pulmonary Hypertension in Patients With Chronic Thromboembolic Pulmonary Disease

Read full text
Authors: Adam Dhayyat, Knut Stavem, Øyvind Jervan, Janne Mykland Hilde, Diyar Mohammed Sediq Rashid, Jostein Gleditsch, Waleed Ghanima, Kjetil Steine
Cited by: 0
References: 23

Abstract

Background This study was aimed at determining whether stress echocardiography could detect exercise pulmonary hypertension (ePH) in patients with mild chronic thromboembolic pulmonary disease (CTEPD) as compared with right‐heart catheterization (RHC). Methods Thirty‐six symptomatic patients with persistent residual perfusion defects detected using ventilation/perfusion scintigraphy underwent a haemodynamic assessment by RHC and echocardiography at rest and during exercise. We compared pulmonary pressures in echocardiography with RHC values using the definitions in current ESC/ERS guidelines for ePH [mean pulmonary artery pressure/cardiac output (mPAP/CO) slope > 3 mmHg/L/min] and PH (mPAP > 20 mmHg). Results Ten of the 36 patients (28%) exhibited an increase in the invasive mPAP/CO slope of > 3 mmHg/L/min. The correlation between echocardiographic and invasive measures of the mPAP/CO slope and systolic pulmonary pressure (sPAP) during peak exercise was ρ = 0.75 (95 % C I = 0.53–0.97) and ρ = 0.75 (95 % C I = 0.53–0.96), respectively. In bivariate logistic regression analyses, ePH was associated with the echocardiographic sPAP during peak exercise [ o d d s r a t i o ( OR ) = 1.13, 95 % C I = 1.02–1.24] and with the echocardiographic mPAP/CO slope ( OR = 3.86, 95 % C I = 1.24–12.03). In ROC analysis, AUC was 0.89 (95 % C I = 0.78–1.00) for the optimal exercise sPAP cut‐off value of 56 mmHg ( s e n s i t i v i t y = 90 % , s p e c i f i c i t y = 87 % ), and 0.84 (95 % C I = 0.66–1.00) for the optimal mPAP/CO slope cut‐off value of 3.7 mmHg/L/min ( s e n s i t i v i t y = 89 % , s p e c i f i c i t y = 79 % ). Conclusion Stress echocardiographic assessments of the exercise sPAP and mPAP/CO slope predicted ePH as measured using RHC with good discrimination and acceptable calibration, providing promising evidence in diagnosing ePH in patients with CTEPD. Trial Registration ClinicalTrials.gov identifier: NCT03405480

Fields of Study & Subjects

Pulmonary Hypertension Research and Treatments Venous Thromboembolism Diagnosis and Management Cardiovascular and Diving-Related Complications

Publication details

Journal / source
Pulmonary Medicine
Volume
2026
Issue
1
Pages
4127338–4127338
Publication date
1 January 2026
Language
EN